Histone deacetylase inhibitors in APL and beyond

K. Petrie, N. Prodromou, Arthur Z Zelent

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In recent years the study of chemical modifications to chromatin and their effects oncellular processes has become increasinglyimportant inthe field of cancer research. Disruptions to the normal epigenetic pattern of the cell can serve as biomarkers and are important determinants of cancer progression. Accordingly, drugs that inhibit the enzymes responsible for modulating these epigenetic markers, in particular histone deacetylases, are the focus of intense research and development. In this chapter we provide an overview of class I and II histone deacetylases as well as a guide to the diverse types of histone deacetylase inhibitors and their activities in the context of APL. We also discuss the rationale for the use of histone deacetylase inhibitors in combination therapy for the treatment of cancer and the current status of clinical trials.

Original languageEnglish (US)
Pages (from-to)157-203
Number of pages47
JournalCurrent Topics in Microbiology and Immunology
Volume313
StatePublished - 2007
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Histone Deacetylases
Epigenomics
Neoplasms
Research
Chromatin
Biomarkers
Clinical Trials
Enzymes
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Microbiology

Cite this

Petrie, K., Prodromou, N., & Zelent, A. Z. (2007). Histone deacetylase inhibitors in APL and beyond. Current Topics in Microbiology and Immunology, 313, 157-203.

Histone deacetylase inhibitors in APL and beyond. / Petrie, K.; Prodromou, N.; Zelent, Arthur Z.

In: Current Topics in Microbiology and Immunology, Vol. 313, 2007, p. 157-203.

Research output: Contribution to journalArticle

Petrie, K, Prodromou, N & Zelent, AZ 2007, 'Histone deacetylase inhibitors in APL and beyond', Current Topics in Microbiology and Immunology, vol. 313, pp. 157-203.
Petrie, K. ; Prodromou, N. ; Zelent, Arthur Z. / Histone deacetylase inhibitors in APL and beyond. In: Current Topics in Microbiology and Immunology. 2007 ; Vol. 313. pp. 157-203.
@article{24472099ea5249cda98ef8fc6c85f544,
title = "Histone deacetylase inhibitors in APL and beyond",
abstract = "In recent years the study of chemical modifications to chromatin and their effects oncellular processes has become increasinglyimportant inthe field of cancer research. Disruptions to the normal epigenetic pattern of the cell can serve as biomarkers and are important determinants of cancer progression. Accordingly, drugs that inhibit the enzymes responsible for modulating these epigenetic markers, in particular histone deacetylases, are the focus of intense research and development. In this chapter we provide an overview of class I and II histone deacetylases as well as a guide to the diverse types of histone deacetylase inhibitors and their activities in the context of APL. We also discuss the rationale for the use of histone deacetylase inhibitors in combination therapy for the treatment of cancer and the current status of clinical trials.",
author = "K. Petrie and N. Prodromou and Zelent, {Arthur Z}",
year = "2007",
language = "English (US)",
volume = "313",
pages = "157--203",
journal = "Current Topics in Microbiology and Immunology",
issn = "0070-217X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Histone deacetylase inhibitors in APL and beyond

AU - Petrie, K.

AU - Prodromou, N.

AU - Zelent, Arthur Z

PY - 2007

Y1 - 2007

N2 - In recent years the study of chemical modifications to chromatin and their effects oncellular processes has become increasinglyimportant inthe field of cancer research. Disruptions to the normal epigenetic pattern of the cell can serve as biomarkers and are important determinants of cancer progression. Accordingly, drugs that inhibit the enzymes responsible for modulating these epigenetic markers, in particular histone deacetylases, are the focus of intense research and development. In this chapter we provide an overview of class I and II histone deacetylases as well as a guide to the diverse types of histone deacetylase inhibitors and their activities in the context of APL. We also discuss the rationale for the use of histone deacetylase inhibitors in combination therapy for the treatment of cancer and the current status of clinical trials.

AB - In recent years the study of chemical modifications to chromatin and their effects oncellular processes has become increasinglyimportant inthe field of cancer research. Disruptions to the normal epigenetic pattern of the cell can serve as biomarkers and are important determinants of cancer progression. Accordingly, drugs that inhibit the enzymes responsible for modulating these epigenetic markers, in particular histone deacetylases, are the focus of intense research and development. In this chapter we provide an overview of class I and II histone deacetylases as well as a guide to the diverse types of histone deacetylase inhibitors and their activities in the context of APL. We also discuss the rationale for the use of histone deacetylase inhibitors in combination therapy for the treatment of cancer and the current status of clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33846975835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846975835&partnerID=8YFLogxK

M3 - Article

C2 - 17217044

AN - SCOPUS:33846975835

VL - 313

SP - 157

EP - 203

JO - Current Topics in Microbiology and Immunology

JF - Current Topics in Microbiology and Immunology

SN - 0070-217X

ER -